Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Jazz Pharmaceuticals has acquired the neuroscience drug firm Cavion for $52.5 million up front. Cavion’s most advanced drug candidate is a small molecule licensed from Merck & Co. Called CX–8998, it targets T-type calcium channels, which are implicated in several neurological diseases, including essential tremor, epilepsy, and Parkinson’s. Cavion has already tested the compound in clinical trials for those three conditions. Cavion shareholders could earn an additional $260 million in milestone payments as the compound undergoes further testing.
This article has been sent to the following recipient: